Results 161 to 170 of about 491,136 (305)

Comparing outcomes using low‐dose apixaban and anti‐Xa monitoring and vitamin K antagonists in patients with renal replacement therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Background Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end‐stage renal disease (ESRD) receiving renal replacement therapy (RRT).
John K. Bartoli‐Abdou   +10 more
wiley   +1 more source

Deep venous thrombosis

open access: yes, 2009
This contribution discusses deep venous thrombosis in the deep veins of the leg and proximal veins of the iliofemoral ...
Smith, Frank C T, Winterborn, Rebecca J
core  

Comparative treatment effects of direct oral anticoagulants versus warfarin for nonvalvular atrial fibrillation in clinical practice vary over time due to channelling

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Temporal shifts in patient characteristics can influence comparative treatment effects within a certain indication. We investigated patient characteristics and comparative effectiveness and safety for direct oral anticoagulants (DOACs) and warfarin over the time period where DOACs replaced warfarin as preferred stroke prophylaxis in patients with ...
Raoul B. L. J. van den Hemel   +6 more
wiley   +1 more source

Advanced In Vitro Platforms for Experimental Liver Research: From Organoids and Liver‐on‐Chip to Omics and Artificial Intelligence

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT Hepatocytes perform essential physiological functions in the human body. Gaining more profound insight into the liver structure, diseases, and physiology by using in vitro models can help to propose more relevant clinical applications. Conventional in vitro liver models, such as two‐dimensional (2D) cell cultures, fail to adequately replicate ...
Seyedeh Kiana Teymorian   +3 more
wiley   +1 more source

Papilledema due to Cerebral Venous Sinus Thrombosis

open access: yes, 2018
The diagnosis of cerebral venous thrombosis is challenging due to a wide range of clinical manifestations. Headache is the most common presenting symptom. Papilledema is present in about 28% of patients with cerebral venous thrombosis.
Minsoo Baek; Changhwan Lee; Moohwan Chang; Jiho Chang; Sungeun Kyung
core  

Intradural Venous Sinus Cyst Mimicking Sinus Vein Thrombosis on Magnetic Resonance Venography

open access: yes
Cerebral venous thrombosis is the obstruction of cranial venous pathways, including thrombosis in the cortical, dural, and deep cerebral veins. It constitutes 0.5%-1% of all strokes and is usually seen in young people. It is slightly more common in young
Barış İrgül   +3 more
core   +1 more source

Glycopolymeric nanoparticles transported by activated platelets protect ischemic myocardium by alleviating PANoptosis through targeting macrophage Dectin‐1

open access: yesBMEMat, EarlyView.
NP‐SF, designed to target macrophage Dectin‐1 and activated platelets, selectively accumulated in ischemic myocardium, where it was taken up by macrophages after platelet hitchhiking. By inhibiting NLRC5‐related PANoptosis, NP‐SF significantly attenuated pathological damage, and effectively preserved cardiac function in a murine ischemia–reperfusion ...
Guanye Yu   +13 more
wiley   +1 more source

Hyperbranched poly‐L‐lysine surface‐engineered bioprosthetic heart valves with anti‐calcification, anti‐infection, and durability

open access: yesBMEMat, EarlyView.
The challenges of bioprosthetic heart valves (BHV) with respect to calcification, infection, and poor durability are tackled by surface engineering of hyperbranched poly‐L‐lysine (HBPL), providing a translational solution to improve long‐term valve performance.
Pai Peng   +7 more
wiley   +1 more source

A Rare Case of Bilateral Rasmussen's Encephalitis with Cortical Venous Thrombosis. [PDF]

open access: yesAnn Indian Acad Neurol
Gupta S, Singh M, Lal MK, Das D, Daga A.
europepmc   +1 more source

Home - About - Disclaimer - Privacy